Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's reported Q2 2027 earnings with a 52.1% gross margin increase sequentially but a 254 basis point year-over-year decline due to lower Lenalidomide sales. EBITDA margin was 20.6%, and profit after tax was ₹9.25 crores. The company highlighted double-digit growth in North America and emerging markets, new product launches, and strategic partnerships. Operating working capital increased to $1.53 billion, with a net cash surplus of ₹2.5 thousand crores.

Original reporting
Published Oct 23, 2026, 4:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$RDYNeutralMed
01

Why it matters

The earnings provide fresh data on revenue mix, margins and EPS, informing valuation and sector outlook.

02

Market read

First disclosure of quarterly results; moderate relevance for traders with exposure to emerging‑market pharma.

03

What to watch

Impact of Middle East supply‑chain disruptions and upcoming semaglutide reload may boost future quarters.

Relevance 7/10Novelty 7/10Timing: post-market

Background

Dr. Reddy's (RDY) released its Q2 FY27 earnings call transcript, detailing financial performance across segments.

Company-level read

Ticker impact

$RDYNeutralMedium confidence
Context

Q2 FY27 earnings call disclosed revenue, margin and EPS figures for the first time.

Expected impact

potential slight downside as margins dip and revenue growth slows in Europe.

Evidence & confidence

First release of quarterly numbers provides new data, but no dramatic surprise; investors may adjust valuations modestly.

Market effects

Highlights pressure on Indian pharma generics margins and potential re‑rating of sector peers.

May influence Indian market sentiment and affect other domestic pharma stocks.

Limited; primarily relevant to investors in emerging‑market pharma exposure.

Counterpoint

Despite margin compression, strong growth in emerging markets could support upside.

Key entities

  • Dr. Reddy's Laboratories Ltd.

    Indian pharmaceutical company listed in the US as RDY.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia